Global Asthma Treatment Market [By Drug Class (Anti-inflammatory, Bronchodilators, and Combination Therapy); By Device Type (Inhalers, Dry Powder, Metered Dose, Soft Mist, and Nebulizers); By Route of Administration (Oral, Inhaled, Intravenous, and Subcutaneous)]; and Geography - Trend, Analysis and Forecast till 2025

Report Summary

TheGlobal Asthma Treatment Marketanticipated to gain traction due to increasing prevalence of asthma cases with critical level of pollution. Asthma is a chronic lung disease which is identified with the symptoms such as shortness of breath, heavy coughing, wheezing, chest tightness, and coughing. Moreover, it is also identified with the indications such as bronchospasm and pulmonary airway obstruction. Asthma is generally caused by ecological or genetic factors or in some cases both factors are responsible for the allergy. Asthma generally starts in childhood and may affect to all age groups. Asthma caused due to allergens and the foreign materials which are harmful to the body. The asthma allergens create lung airway inflammation by making the airway sensitive to the allergic reaction resulting in shortness of breath.

Air pollution is one most common type of allergen causing asthma. In addition, other allergens include pollens, tobacco smoke, chemical smoke, molds, house dust mites in carpets, bedding and furniture wastes, pet dander, and others. Patients with a family history of asthma and allergies are more probable cause to develop asthma. Asthma may get through various types. For instance, asthma caused by allergen is known as allergic asthma. Whereas, in some cases, healthy person can develop asthma and related symptoms during heavy physical activities or exercise. This condition is identified as exercise-induced asthma (EIA).

Increasing awareness for the early diagnosis of asthma and benefits of its diagnosis is anticipated to boost the global Asthma Treatment market growth

Rising prevalence of asthma cases and increasing pollution level are the major factors propelling the global market growth. According to the world health organization (WHO) every year, approximately 110,000 million new asthma diagnosis cases are filed every year in the U.S. this number is anticipated to increase in the forecast year. This high incidence of the asthma cases requiring treatment is expected to bolster the market growth. In addition, the increasing critical level of pollution is further marked as a factor enhancing the market growth. Asthma-related transience in children are mainly prohibited by consciousness, on time treatment and increasing education, thus, increasing consciousness about asthma treatment in children is a lucrative opportunity for asthma drug manufacturers. In addition, swelling smoker population, rise in per head income, increasing government expenses, increasing consciousness about the welfares of timely diagnosis of asthma and rising demand for improved healthcare services are projected to drive the market for asthma treatment.

However, high cost associated with the treatment of the asthma-allergy is anticipated to hinder the market growth. Moreover, cost of immune therapy and associated risk of side effect is the factor expected to become a hurdle for global asthma market.

Global Asthma Treatment Market Taxonomy

全球哮喘治疗市场分割the basis of drug class, device type, route of administration, and geography.

On the basis ofdrug class, the global asthma treatment market is segmented into:

• Anti-inflammatory
• Bronchodilators
• Combination Therapy

On the basis ofdevice type, the global asthma treatment market is segmented into:

• Inhalers
• 干粉
• 计量Dose
• Soft Mist
• Nebulizers

On the basis ofroute of administration, the global asthma treatment market is segmented into:

• Oral
• Inhaled
• Intravenous
• Subcutaneous

On the basis of geography, the global asthma treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

The investment in R&D to manufacturing Novel biologics diminishing the use of generic products

In terms of segmentation the drug class segment is estimated to dominate the global asthma treatment market. The high effectiveness of the designated drugs and the acceptance proportions of asthma therapies related to the dual-action treatment accounted for the major market share in comparison to other drugs. In addition, continuous efforts of market players to produce novel drugs is another major factor enhancing the global growth of drug class segment. For instance, combined products such as Lebrikizumab, and Duplimab are expected to launch the product pipeline including Cinqair, further propelling the growth of anti-allergenic and anti-inflammatory drugs by shrinking the usage of the generic drug.

Increasing asthma cases at the critical level typically in children to generate lucrative opportunities in North America.

On the basis of geography, North America is estimated to dominate the global asthma treatment market. Rising prevalence of asthma cases in U.S. and Canada and the growing demand for anti-inflammatory drugs to control the asthma is the factor for the major market share of North America. For instance, according to American Academy of Allergy Asthma & Immunology (AAAAI) 2015, of almost half of people had the asthma attack. Moreover, children affected by asthma have higher rates in comparison to adults. Moreover, increasing implementation of inhaled therapeutics, government support to provide better healthcare infrastructure, and increased responsiveness levels relating to economical treatment options are another factors for the major market shares in North America.

Asia Pacific region is anticipated to make a dominating growth during the forecast period. The increasing pollution at the critical level, growing number of people affected by asthma and rising government support for the allergy treatments are anticipated to mark Asia Pacific as a dominating region.

Major key players in Asthma Treatment Market

• AstraZeneca Plc
• Philips Healthcare
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline Plc
• Sanofi-Aventis SA
• CareFusion Corporation
• Sunovion Pharmaceuticals, Inc.
• Boehringer Ingelheim GmbH
• Roche Diagnostics
• Merck & Co., Inc.